DCAL

Dishman Carbogen Amcis Share Price

 

 

Invest in Dishman Carbogen Amcis with 2.03X leverage

Invest with MTF

Performance

  • Low
  • ₹253
  • High
  • ₹263
  • 52 Week Low
  • ₹178
  • 52 Week High
  • ₹322
  • Open Price₹261
  • Previous Close₹263
  • Volume150,897
  • 50 DMA₹252.41
  • 100 DMA₹255.08
  • 200 DMA₹250.53

Investment Returns

  • Over 1 Month + 15.67%
  • Over 3 Month -8.94%
  • Over 6 Month + 1.75%
  • Over 1 Year -2.23%

Smart Investing Starts Here Start SIP with Dishman Carbogen Amcis for Steady Growth!

Invest Now

Dishman Carbogen Amcis Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 29.2
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 3,984
  • P/B Ratio
  • 0.6
  • Average True Range
  • 10.65
  • EPS
  • 9.53
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.38
  • RSI
  • 51.98
  • MFI
  • 55.88

Dishman Carbogen Amcis Financials

Dishman Carbogen Amcis Technicals

EMA & SMA

Current Price
₹254.11
-9.22 (-3.5%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹252.90
  • 50 Day
  • ₹252.41
  • 100 Day
  • ₹255.08
  • 200 Day
  • ₹250.53

Resistance and Support

256.8 Pivot Speed
  • R3 270.47
  • R2 266.81
  • R1 260.46
  • S1 250.45
  • S2 246.79
  • S3 240.44

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Dishman Carbogen Amcis Ltd. is a leading global contract research and manufacturing organization (CRMO) based in India, specializing in pharmaceutical and biotechnology services. The company focuses on providing high-quality, innovative solutions in API production and custom synthesis.

Dishman Carbogen Amcis has an operating revenue of Rs. 2,759.38 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 1% needs improvement, ROE of 0% is poor and needs improvement. The company has a reasonable debt to equity of 20%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 200DMA and around 6% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 21% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 66 which is a FAIR score but needs to improve its earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 72 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Dishman Carbogen Amcis Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-12-27 To consider Fund Raising
2025-11-04 Quarterly Results
2025-08-12 Quarterly Results & Fund raising
2025-05-21 Audited Results
2025-03-12 To consider Fund Raising Inter alia, to consider 1. Proposal of fund raising by way of issuance of Non-Convertible Debentures, by way of private placement, subject to such regulatory or statutory approvals as may be required.

Dishman Carbogen Amcis F&O

Dishman Carbogen Amcis Shareholding Pattern

59.32%
1.08%
0%
8.07%
0%
26.84%
4.69%

About Dishman Carbogen Amcis

  • NSE Symbol
  • DCAL
  • BSE Symbol
  • 540701
  • Managing Director
  • Mr. Arpit J Vyas
  • ISIN
  • INE385W01011

Similar Stocks to Dishman Carbogen Amcis

Dishman Carbogen Amcis FAQs

Dishman Carbogen Amcis share price is ₹254 As on 15 January, 2026 | 10:54

The Market Cap of Dishman Carbogen Amcis is ₹3984 Cr As on 15 January, 2026 | 10:54

The P/E ratio of Dishman Carbogen Amcis is 29.2 As on 15 January, 2026 | 10:54

The PB ratio of Dishman Carbogen Amcis is 0.6 As on 15 January, 2026 | 10:54

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23